# Inhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2

## TL;DR

Inhaling exosomes with ACE2 can protect against SARS-CoV-2 infection by blocking the virus from entering cells.

## Contribution

ACE2-expressing exosomes from lung spheroid cells show broad-spectrum protection against SARS-CoV-2 variants.

## Key findings

- LSC-Exo binds and neutralizes SARS-CoV-2 in vitro and in vivo.
- Inhalation of LSC-Exo protects mice and hamsters from SARS-CoV-2-induced disease.
- LSC-Exo is effective against multiple SARS-CoV-2 variants and reduces viral loads.

## Abstract

Continued emergence of SARS-CoV-2 variants of concern that are capable of escaping vaccine-induced immunity highlights the urgency of developing new COVID-19 therapeutics. An essential mechanism for SARS-CoV-2 infection begins with the viral spike protein binding to the human ACE2. Consequently, inhibiting this interaction becomes a highly promising therapeutic strategy against COVID-19. Herein, we demonstrate that ACE2-expressing human lung spheroid cells (LSC)-derived exosomes (LSC-Exo) could function as a prophylactic agent to bind and neutralize SARS-CoV-2, protecting the host against SARS-CoV-2 infection. Inhalation of LSC-Exo facilitates its deposition and biodistribution throughout the whole lung in a female mouse model. We show that LSC-Exo blocks the interaction of SARS-CoV-2 with host cells in vitro and in vivo by neutralizing the virus. LSC-Exo treatment protects hamsters from SARS-CoV-2-induced disease and reduced viral loads. Furthermore, LSC-Exo intercepts the entry of multiple SARS-CoV-2 variant pseudoviruses in female mice and shows comparable or equal potency against the wild-type strain, demonstrating that LSC-Exo may act as a broad-spectrum protectant against existing and emerging virus variants.

Inhibiting SARS-CoV-2 interaction with ACE2 is a promising antiviral strategy. Here, the authors show that exosomes derived from human lung spheroid cells expressing hACE2 accumulate in the lung following prophylactic inhalation to bind and neutralize SARS-CoV-2 and protect mice from SARS-CoV-2-induced disease.